• <em>PAM</em> variants in patients with thyrotrophinomas, cyclical Cushing's disease and prolactinomas
• A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas
• A study on the correlations of PRL levels with anxiety, depression, sleep, and self-efficacy in patients with prolactinoma
• Alternations of Blood Pressure Following Surgical or Drug Therapy for Prolactinomas
• An aggressive cabergoline-resistant, temozolomide-responsive macroprolactinoma due to a germline <em>SDHB</em> pathogenic variant in the absence of paraganglioma or pheochromocytoma
• An unusual concomitance of acute heart failure: prolactinoma in a patient with left ventricular dysfunction-a case report
• Apoplexy of a giant clival ectopic prolactinoma: A very rare case report
• Aromatase inhibitors as a therapeutic strategy for male prolactinoma resistant to dopamine agonists: a retrospective cohort study and literature review
• Benign and Malignant Tumors of the Pituitary Gland
• Between a rock and a hard place: the role of DA induced tumor fibrosis in prolactinoma management
• Bromocriptine sensitivity in bromocriptine-induced drug-resistant prolactinomas is restored by inhibiting FGF19/FGFR4/PRL
• C4 to C7 Laminoplasty for Resection of an Intradural Intramedullary Ependymoma: 2-Dimensional Operative Video
• Cabergoline targets multiple pathways to inhibit PRL secretion and increases stromal fibrosis
• Case report: Complete restoration of the HPA axis function in Cushing's disease with drug treatment
• Case Report: Multiple prolactinomas in a young man with Kallmann syndrome and familial hypocalciuric hypercalcemia
• Challenges in Diagnosis and Treatment of Male Hypogonadism
• Clinical and radiographic characteristics of patients with non-functioning pituitary adenomas categorized according to their serum prolactin concentration: novel predictors of postoperative transient diabetes insipidus following surgery
• Clinical Characteristics and Outcomes of Prolactinomas in Children and Adolescents: A Large Retrospective Cohort Study
• Clinical characteristics of male prolactinoma patients mainly presenting with severe obesity and the metabolic response to dopamine agonist therapy
• Clinically active pituitary tumors
• Clival ectopic pituitary prolactinoma was successfully managed by transsphenoidal surgery: A rare case report
• Coexistence of Micro-Prolactinoma and Mayer-Rokitansky-Kuster-Hauser Syndrome- A Rare Association
• Commentary: Clinical characteristics of male prolactinoma patients mainly presenting with severe obesity and the metabolic response to dopamine agonist therapy
• Consecutive resections of double pituitary adenoma for resolution of Cushing disease: illustrative case
• Correction: Aromatase inhibitors as a therapeutic strategy for male prolactinoma resistant to dopamine agonists: a retrospective cohort study and literature review
• Correlation Between Pituitary Adenoma Surgery and Anxiety Disorder: Systematic Review and Meta-Analysis
• Curcumin affects autophagy of prolactinoma cells by upregulating miR-206 to exert antitumor effects
• Determining Ideal Management for Patients With Coexisting Prolactinomas and Psychiatric Symptoms: A Systematic Review
• Diagnosis of hyperprolactinemia in women: A Position Statement from the Brazilian Federation of Gynecology and Obstetrics Associations (Febrasgo) and the Brazilian Society of Endocrinology and Metabolism (SBEM)
• Dopamine Agonists as a Novel "Cure" for Autoimmune Diabetes
• Efficacy and Safety of Endoscopic Transsphenoidal Resection for Prolactinoma: A Retrospective Multicenter Case-series
• Endoscopic endonasal surgery for prolactinomas: prognostic factors for disease control and management of persistent disease
• Endoscopic Endonasal Transcavernous Hemipituitary Transposition for Resection of Invasive Prolactinoma: 2-Dimensional Operative Video
• Gender Differences in Patients with Prolactinoma: Single-center Ukrainian Experience
• Gender-specific prolactin thresholds to determine prolactinoma size: a novel Bayesian approach and its clinical utility
• Genetic testing in prolactinomas: a cohort study
• Genomics, Transcriptomics, and Epigenetics of Sporadic Pituitary Tumors
• Hotspots of Somatic Genetic Variation in Pituitary Neuroendocrine Tumors
• Hyperprolactinemia Due to Prolactinoma has an Adverse Impact on Bone Health with Predominant Impact on Trabecular Bone: A Systematic Review and Meta-Analysis
• Hyperprolactinemia in the postmenopause: versions and contraversions
• Identification of Prolactinoma in Pituitary Neuroendocrine Tumors Using Radiomics Analysis Based on Multiparameter MRI
• Impact of medical therapy for hormone-secreting Pituitary tumors on bone
• Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy
• Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study
• Impulse Control Disorders in Patients with Pituitary Tumors Treated with Dopamine Agonists: A Systematic Review
• Impulse Control Disorders in Southern Iraqi Patients Medicated With Cabergoline for Prolactinoma
• Increased prevalence of germline pathogenic CHEK2 variants in individuals with pituitary adenomas
• Long-term use of clomiphene in male macroprolactinomas with persistent hypogonadism
• Macroprolactin over time: Is there any point in rechecking it in people with a persistently elevated serum prolactin?
• Medically responsive amyloidogenic giant sellar-parasellar prolactinoma
• Metabolic and inflammatory parameters in relation to baseline characterization and treatment outcome in patients with prolactinoma: insights from a retrospective cohort study at a single tertiary center
• Metabolic Disorders During Prolactinomas
• Metastatic pituitary neuroendocrine neoplasms: A case report of a malignant prolactinoma
• Muscle function, exercise capacity, physical activity level and cardiovascular disease risk factor knowledge in patients with prolactinoma
• Network pharmacology analysis and molecular mechanism of paeoniflorin and its metabolite in prolactinoma cells
• Nonalcoholic Fatty Liver Disease, Bone and Muscle Quality in Prolactinoma: A Pilot Study
• Overcoming therapy resistance in prolactinomas: from perspectives to real clinical practice
• Paradoxical effect of dopamine-agonists on IGF-1 in patients with prolactinoma: the role of weight
• Pediatric Cluster Headache Case Series: Symptomatic Cases and the Migraine Relationship
• Phosphorylation of PBK at Thr9 by CDK5 correlates with invasion of prolactinomas
• Pituitary Adenoma Prevalence and Characteristics of Omani Patients: A Single Center Experience
• Pituitary apoplexy in endocrinologically silent adenoma during somatostatin analog administration for pancreatic neuroendocrine tumor: A case report
• Pituitary dysfunction following mild traumatic brain injury in female athletes
• Pituitary macroadenoma with panhypopituitarism masquerading as schizophrenia: a diagnostic dilemma managed conservatively
• Pituitary tumor registry: a multidisciplinary program protocol
• Pituitary tumors and the risk of other malignancies: is the relationship coincidental or causal?
• Pregnancy-induced prolactinoma enlargement
• Presurgical Medical Treatment in Prolactinomas: Surgical Implications and Pathological Characteristics from 290 Cases
• Primary Sellar Neuroblastoma Masquerading as a Pituitary Macroadenoma
• Prognostic factors for surgical treatment of prolactin-secreting pituitary adenomas
• Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment
• Prolactin-secreting tumors, dopamine agonists and pregnancy: a longitudinal experience of a tertiary neuroendocrine center
• Prolactinoma - which patients react favorably to cabergoline medication?
• Prolactinoma and Adenomyosis - More than Meets the Eye: A Case Report
• Prolactinoma in postmenopausal women: a systematic review
• Prolactinoma: Navigating the Dual Challenge of Side Effects and Treatment Strategies - A Comprehensive Review
• Quality of life in Prolactinoma: A systematic review
• Reply to 'Tumour fibrosis in dopamine agonist-exposed prolactinomas is a diminishing concern'
• Reply to the Letter to the Editor on "Prolactin is a Key Factor for Nonalcoholic Fatty Liver Disease in Obese Children"
• Risk Assessment of Diabetes Mellitus during and after Pregnancy in Women with Prolactinomas
• Role of Medical and Surgical Treatment in Management of the Patients With Prolactinoma; Single-Center Experience
• Serum prolactin levels and mortality in adults without prolactinoma: A meta-analysis
• Sporadic pituitary adenoma with somatic double-hit loss of MEN1
• Suddenly confused: Necessity for timely follow-up after elective prolactinoma resection
• Surveillance imaging strategies for pituitary adenomas: when, how frequent and when to stop
• Surveillance Imaging Strategies for Pituitary Adenomas: When, How Frequent, and When to Stop
• Synchronous presentation of prolactinoma and supratentorial tanycytic ependymoma
• TEMPORAL LOBE HERNIATION AND CHIASMOPATHY DURING DOPAMINE AGONIST THERAPY FOR PROLACTINOMA
• The Application of Pneumatic Arm in Neuroendoscopic Transsphenoidal Pituitary Adenoma Resection
• The challenges in the management of giant prolactinoma in young man
• The Effect of Antipsychotics on Prolactinoma Growth: A Radiological and Serological Analysis
• The Effect of Preoperative Cabergoline on Prolactinoma Fibrosis: A Case Series
• The RAPID Consortium: A Platform for Clinical and Translational Pituitary Tumor Research
• The research trend of hyperprolactinemia from 2011 to 2023 was analyzed by bibliometrics
• The Role of Artificial Intelligence in Endocrine Management: Assessing ChatGPT's Responses to Prolactinoma Queries
• The role of surgical management for prolactin-secreting tumors in the era of dopaminergic agonists: An international multicenter report
• The Use of the Suboccipital Transtentorial Approach to the Posterior Inferior Incisural Space
• The Value of ER∝ in the Prognosis of GH- and PRL-Secreting PitNETs: Clinicopathological Correlations
• Treatment of hyperprolactinemia in women: A Position Statement from the Brazilian Federation of Gynecology and Obstetrics Associations (Febrasgo) and the Brazilian Society of Endocrinology and Metabolism (SBEM)
• Tumour fibrosis in dopamine agonist-exposed prolactinomas is a diminishing concern